NovoMix® 50 and 70

:Type 1 and 2 diabetes
:Filed for registration



NovoMix® 50: Launched in Europe, approved in the US and Japan
NovoMix® 70: Launched in Europe and approved in Japan

The aim is to develop and market other premixed formulations of the rapid acting insulin analogue - insulin aspart - as part of a biphasic insulin aspart product range. NovoMix® 50 and NovoMix® 70 will be linked to the introduction of a three times daily concept in type 1 and type 2 diabetes for superior glycaemic control without increasing theriskof hypoglycaemia, hence NovoMix® 50 and NovoMix® 70 are targeted towards more intensified premix therapy.

Company announcements
Novo Nordisk insulin analogues have proven safety profiles (28 Jun 2009)
Novo Nordisk refocuses its activities within inhaled insulin and discontinues the development of AERx® (14 Jan 2008)
Novo Nordisk announces major expansion of its diabetes care field force in the US (30 Nov 2006)
Read more company announcements

Press releases
The 4-T study of intensified insulin regimens shows excellent three-year glucose control with low risk of hypoglycaemia in type 2 diabetes (22 Oct 2009)
New data shows that type 2 diabetes patients who start insulin therapy with once-daily NovoMix® 30 achieve significantly greater HbA1c reduction than with insulin glargine. 1 (02 Oct 2009)
New study directly comparing insulin delivery devices shows that Next Generation FlexPen® has a significantly lower injection force than SoloStar® and KwikPen® (29 May 2009)
Read more press releases

Scientific abstracts
Advances in Therapy (2008)
American Journal of Physiology-Endocrinology and Metabolism (2004)
Biochemistry (2005)
Read more scientific abstracts
  •